Attached files
file | filename |
---|---|
10-K - FORM 10-K - CUMBERLAND PHARMACEUTICALS INC | g26446e10vk.htm |
EX-31.2 - EX-31.2 - CUMBERLAND PHARMACEUTICALS INC | g26446exv31w2.htm |
EX-31.1 - EX-31.1 - CUMBERLAND PHARMACEUTICALS INC | g26446exv31w1.htm |
EX-23.1 - EX-23.1 - CUMBERLAND PHARMACEUTICALS INC | g26446exv23w1.htm |
EX-10.13 - EX-10.13 - CUMBERLAND PHARMACEUTICALS INC | g26446exv10w13.htm |
EX-10.12 - EX-10.12 - CUMBERLAND PHARMACEUTICALS INC | g26446exv10w12.htm |
EX-10.26 - EX-10.26 - CUMBERLAND PHARMACEUTICALS INC | g26446exv10w26.htm |
EX-10.15 - EX-10.15 - CUMBERLAND PHARMACEUTICALS INC | g26446exv10w15.htm |
EX-10.11 - EX-10.11 - CUMBERLAND PHARMACEUTICALS INC | g26446exv10w11.htm |
Exhibit 32.1
CERTIFICATION
OF CHIEF EXECUTIVE OFFICER
AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Cumberland
Pharmaceuticals Inc. (the Company) on
Form 10-K
for the fiscal year ended December 31, 2010, as filed with
the Securities and Exchange Commission on the date hereof (the
Report), I, A.J. Kazimi, Chief Executive
Officer, and David L. Lowrance, Vice President and Chief
Financial Officer, of the Company, certify, pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
(18 U.S.C. section 1350), that, based on my knowledge:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ A. J. Kazimi
A.J. Kazimi
Chief Executive Officer
March 11, 2011
Chief Executive Officer
March 11, 2011
/s/ David L. Lowrance
David L. Lowrance
Vice President and Chief Financial Officer
March 11, 2011
Vice President and Chief Financial Officer
March 11, 2011